- High demand product with blockbuster drug good for opiod crisis.
- Potential replacement for morphine, no real competitor
- Partnership with Syneos for sales
- Potential buyout
Good levels to buy at 2.50 and 2.33
Should see rise towards next quarter .
Long term PTs
TP1 - $5
TP2 - $15
TP3 - $30
Falling wedge pattern in the short term and an ascending triangle on the mid term.
Continue hold towards next quarter earnings in March